![]() Pfizer is the first pharma partner to contribute drugs for this study, but Strata has not disclosed which drugs will be evaluated in the trial, nor the biomarker-defined indications of interest. The database includes cancer patients' genomic and transcriptomic profiles, as well as their treatment outcomes. Strata is drawing on information in its clinical-molecular database to identify the new biomarker-informed, pan-tumor drug indications it is exploring in its platform trial. The WIN Consortium used genetic sequencing and transcriptomics to match patients to treatment arms in the WINTHER trial. Strata oncology trial#The American Society of Clinical Oncology's TAPUR trial is one such effort and has reported out several positive arms. Platform trials are increasingly being used to discover novel, biomarker-defined indications of approved cancer therapies. Patients cannot have previously received a drug in the same class as the treatment they match to. In order to join the study, patients must have exhausted standard lines of therapy and have biomarker profiles that match to specific treatment arms when assessed by the 429-gene StrataNGS test. The company doesn't have an official launch date but expects to begin the trial soon. The Ann Arbor, Michigan-based molecular profiling firm expects other pharmaceutical companies will join after the study is launched. ![]() So far, Pfizer has partnered with Strata to provide drugs to advanced solid tumor patients in four arms of the platform trial, dubbed Strata Precision Indications for Approved Therapies, or Strata PATH. ![]() The platform, which integrates comprehensive genomic profiling and highly quantitative RNA expression profiling, enables comprehensive molecular insights from a single, minute tumor tissue specimen.NEW YORK – Strata Oncology on Tuesday said it will conduct a study to evaluate new biomarker-defined indications for targeted therapies and immunotherapies already approved by the US Food and Drug Administration. Led by Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology is a precision oncology company involved in expanding its comprehensive genomic and transcriptomic profiling platform to deliver a portfolio of treatment selection tests for solid tumors. The proceeds will be used to accelerate the development of Strata Oncology’s personalized minimal residual disease (MRD) assay for early-stage cancers and advance its pipeline of novel RNA-based treatment selection tests for solid tumors. Strata Oncology’s existing investors, including Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital and Renaissance Venture Capital Fund also participated in the financing, which brings the company’s total raised to date to over $130m since inception. ![]() Wellington Management led the financing and was joined by other new investors including Cormorant Asset Management, Monashee Investment Management and Highside Capital Management. Strata oncology series#Strata Oncology, Inc., an Ann Arbor, Mich.-based precision oncology company advancing molecular indications for cancer therapies, raised $90m in Series C financing. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |